+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Short Bowel Syndrome Market by Treatment Type (Oral Supplementation, Parenteral Nutrition, Pharmacological Therapy), Product Type (Adjunctive Therapies, Enteral Formulas, Pharmacologics), Route Of Administration, End Use, Patient Age, Etiology - Global Forecast 2025-2030- Product Image
Short Bowel Syndrome Market by Treatment Type (Oral Supplementation, Parenteral Nutrition, Pharmacological Therapy), Product Type (Adjunctive Therapies, Enteral Formulas, Pharmacologics), Route Of Administration, End Use, Patient Age, Etiology - Global Forecast 2025-2030- Product Image
Sale

Short Bowel Syndrome Market by Treatment Type (Oral Supplementation, Parenteral Nutrition, Pharmacological Therapy), Product Type (Adjunctive Therapies, Enteral Formulas, Pharmacologics), Route Of Administration, End Use, Patient Age, Etiology - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011692
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Short Bowel Syndrome market is undergoing rapid transformation, driven by advancing therapies, shifting regulations, and heightened focus on patient-centric care. For senior decision-makers, navigating this evolving landscape requires nuanced insight into therapeutic innovations, supply chain complexities, and the strategic moves of leading industry stakeholders.

Market Snapshot: Short Bowel Syndrome Market Growth and Outlook

The Short Bowel Syndrome market expanded robustly from USD 966.42 million in 2024 to USD 1.16 billion in 2025, with a projected CAGR of 19.35%. This trajectory points to continued strength, with revenues forecast to reach USD 2.79 billion by 2030, reflecting sustained momentum in therapeutic development and market adoption.

Scope & Segmentation

This comprehensive market research report covers an extensive range of segments and emerging technologies set to shape Short Bowel Syndrome management globally. The analysis delves beyond the core market to provide actionable segmentation and strategic context.

  • Treatment Types: Covers oral supplementation, parenteral nutrition, pharmacological therapy, and surgical intervention. Each category includes approaches such as dietary supplements, nutritional formulas, antibiotics, growth factors, hormonal agents, bowel transplantation, and intestinal lengthening procedures.
  • Product Types: Encompasses adjunctive therapies (probiotics, vitamins, minerals), enteral formulas (elemental, polymeric, semi-elemental), pharmacologics (such as teduglutide), and parenteral nutrition (amino acid, carbohydrate, and lipid solutions).
  • Routes of Administration: Focuses on intravenous and oral modalities, providing critical distinction for clinical protocols.
  • End Use: Analyzes applications in home care facilities, hospitals, and specialty clinics, reflecting diverse delivery settings.
  • Patient Age: Considers distinct requirements among adult, geriatric, and pediatric populations.
  • Etiology: Segment by underlying causes, specifically congenital conditions, Crohn disease, and mesenteric ischemia.
  • Geographic Regions: Assesses the Americas (U.S. with state-level granularity, Canada, Mexico, Brazil, Argentina), Europe, Middle East, and Africa (including key economies such as the United Kingdom, Germany, France, Saudi Arabia, South Africa, Nigeria, Turkey, and others), and Asia-Pacific (featuring China, India, Japan, Australia, Korea, and Southeast Asian countries).
  • Key Companies Profiled: In-depth review of industry leaders like Ajinomoto Co., Inc.; Terumo Corporation; Becton, Dickinson and Company; ICU Medical, Inc.; Smiths Medical; Otsuka Holdings; Lonza Group; CordenPharma; Gland Pharma; and Hikma Pharmaceuticals.

Key Takeaways for Decision-Makers

  • The Short Bowel Syndrome market’s evolution is propelled by next-generation biologic therapies, innovative enteral formulations, and integration of digital health tools, collectively enhancing clinical outcomes.
  • Patient advocacy and increasing regulatory momentum are fueling the adoption of individualized care models and accelerating patient access to novel interventions.
  • Stakeholders are leveraging real-world evidence to support new product adoption, with R&D focusing on formulations attuned to the unique absorbency challenges of the syndrome.
  • Regional strategies, tailored to local reimbursement policies and infrastructure capabilities, are proving crucial—particularly where access disparities or tariff implications are evident.
  • Corporate maneuvers such as partnerships, data-driven support platforms, and manufacturing localization are enabling sustained value creation and positioning for future growth.
  • Investment in educating both healthcare professionals and patients remains a driver for increased market penetration and therapy optimization.

Tariff Impact: Navigating 2025 U.S. Trade Policy Changes

The introduction of new tariff schedules in the United States in 2025 has triggered increased procurement costs for key nutritional components and parenteral supplies. Distributors and care providers are reassessing sourcing strategies, leading to growing interest in domestic manufacturing partnerships, use of free trade zones, and negotiating long-term supply agreements to maintain consistent access and cost effectiveness. Pricing recalibrations have resulted in selective adoption of alternative protocols to manage budgets, fostering a broader push toward resilient, diversified supply chains.

Methodology & Data Sources

This report applies qualitative and quantitative research methods, including interviews with clinical experts, pharmacists, and patient advocates, paired with analysis of peer-reviewed literature, regulatory filings, and industry data. Triangulation of varied sources, such as supplier catalogs and reimbursement guidelines, ensures data integrity and supports the depth of competitive intelligence presented.

Why This Report Matters

  • It equips executives with rigorous, segmented analysis of treatment modalities, product innovations, and evolving patient demographics, supporting informed investment and resource allocation.
  • Market entry and expansion strategies are underpinned by detailed regional assessments and clear implications of supply chain and policy developments, including latest regulatory and tariff environments.
  • Stakeholders can anticipate shifts in competitive positioning, optimize partnerships, and identify opportunity areas to enhance both clinical and commercial outcomes.

Conclusion

This analysis provides actionable insights into the Short Bowel Syndrome market’s evolving terrain. Senior leaders will be prepared to adapt strategy, advance innovation, and contribute meaningfully to improved patient care in a rapidly changing global market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging glucagon-like peptide-2 analog therapies expanding treatment options for short bowel syndrome
5.2. Advancements in intestinal lengthening surgical techniques improving patient outcomes in adults
5.3. Growing adoption of home parenteral nutrition delivery systems enhancing quality of life in SBS patients
5.4. Emerging regenerative medicine and tissue engineering approaches targeting intestinal mucosa restoration
5.5. Integration of telehealth services for nutritional management improving patient monitoring and adherence
5.6. Increasing focus on microbiome modulation therapies to reduce complications and support intestinal adaptation
5.7. Evolving reimbursement and pricing strategies impacting access to specialized SBS treatments across regions
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Short Bowel Syndrome Market, by Treatment Type
8.1. Introduction
8.2. Oral Supplementation
8.2.1. Dietary Supplements
8.2.2. Nutritional Formulas
8.3. Parenteral Nutrition
8.3.1. Customized Pn
8.3.2. Standard Pn
8.4. Pharmacological Therapy
8.4.1. Antibiotics
8.4.2. Growth Factors
8.4.3. Hormonal Agents
8.5. Surgical Intervention
8.5.1. Bowel Transplantation
8.5.2. Intestinal Lengthening Procedures
9. Short Bowel Syndrome Market, by Product Type
9.1. Introduction
9.2. Adjunctive Therapies
9.2.1. Probiotics
9.2.2. Vitamins And Minerals
9.3. Enteral Formulas
9.3.1. Elemental Formulas
9.3.2. Polymeric Formulas
9.3.3. Semi-elemental Formulas
9.4. Pharmacologics
9.4.1. Teduglutide
9.5. Pn Solutions
9.5.1. Amino Acid Solutions
9.5.2. Carbohydrate Solutions
9.5.3. Lipid Emulsions
10. Short Bowel Syndrome Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. Short Bowel Syndrome Market, by End Use
11.1. Introduction
11.2. Home Care Facilities
11.3. Hospitals
11.4. Specialty Clinics
12. Short Bowel Syndrome Market, by Patient Age
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Short Bowel Syndrome Market, by Etiology
13.1. Introduction
13.2. Congenital Conditions
13.3. Crohn Disease
13.4. Mesenteric Ischemia
14. Americas Short Bowel Syndrome Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Short Bowel Syndrome Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Short Bowel Syndrome Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Ajinomoto Co., Inc.
17.3.2. Terumo Corporation
17.3.3. Becton, Dickinson and Company
17.3.4. ICU Medical, Inc.
17.3.5. Smiths Medical (Smiths Group plc)
17.3.6. Otsuka Holdings Co., Ltd.
17.3.7. Lonza Group AG
17.3.8. CordenPharma International AG
17.3.9. Gland Pharma Limited
17.3.10. Hikma Pharmaceuticals PLC
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. SHORT BOWEL SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. SHORT BOWEL SYNDROME MARKET: RESEARCHAI
FIGURE 28. SHORT BOWEL SYNDROME MARKET: RESEARCHSTATISTICS
FIGURE 29. SHORT BOWEL SYNDROME MARKET: RESEARCHCONTACTS
FIGURE 30. SHORT BOWEL SYNDROME MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SHORT BOWEL SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 171. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 172. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 173. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
TABLE 174. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2030 (USD MILLION)
TABLE 175. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
TABLE 176. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2030 (USD MILLION)
TABLE 177. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
TABLE 178. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2030 (USD MILLION)
TABLE 179. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
TABLE 180. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
TABLE 181. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 182. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 183. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 184. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 185. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
TABLE 186. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2030 (USD MILLION)
TABLE 187. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
TABLE 188. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2030 (USD MILLION)
TABLE 189. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
TABLE 190. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2030 (USD MILLION)
TABLE 191. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 194. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 195. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 196. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 197. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
TABLE 198. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2030 (USD MILLION)
TABLE 199. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 200. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 201. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
TABLE 202. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2030 (USD MILLION)
TABLE 203. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
TABLE 204. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2030 (USD MILLION)
TABLE 205. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
TABLE 206. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2030 (USD MILLION)
TABLE 207. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
TABLE 208. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
TABLE 209. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 210. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 211. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 212. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 213. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
TABLE 214. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2030 (USD MILLION)
TABLE 215. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
TABLE 216. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2030 (USD MILLION)
TABLE 217. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
TABLE 218. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2030 (USD MILLION)
TABLE 219. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 222. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 223. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 224. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 225. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
TABLE 226. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
TABLE 316. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
TABLE 318. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2030 (USD MILLION)
TABLE 319. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
TABLE 320. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2030 (USD MILLION)
TABLE 321. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
TABLE 322. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET

Samples

Loading
LOADING...

Companies Mentioned

  • Ajinomoto Co., Inc.
  • Terumo Corporation
  • Becton, Dickinson and Company
  • ICU Medical, Inc.
  • Smiths Medical (Smiths Group plc)
  • Otsuka Holdings Co., Ltd.
  • Lonza Group AG
  • CordenPharma International AG
  • Gland Pharma Limited
  • Hikma Pharmaceuticals PLC

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.16 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.79 Billion
Compound Annual Growth Rate19.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Short Bowel Syndrome (SBS) - Global Strategic Business Report - Product Image

Short Bowel Syndrome (SBS) - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Short Bowel Syndrome Drug Pipeline Analysis Report 2025 - Product Image

Short Bowel Syndrome Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Short Bowel Syndrome - Epidemiology Forecast - 2034 - Product Image

Short Bowel Syndrome - Epidemiology Forecast - 2034

  • Report
  • 66 Pages
  • Global
From
Gastrointestinal Diseases Therapeutics Market by Indication, Drug Class, Route Of Administration, Distribution Channel, Dosage Form, End User - Global Forecast 2025-2030 - Product Image

Gastrointestinal Diseases Therapeutics Market by Indication, Drug Class, Route Of Administration, Distribution Channel, Dosage Form, End User - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From

About the Short Bowel Syndrome Drug Market

Short Bowel Syndrome (SBS) is a rare disorder that affects the small intestine, resulting in malabsorption of nutrients and fluids. It is typically caused by the surgical removal of a large portion of the small intestine, or by a congenital defect. Treatment for SBS typically involves the use of specialized drugs to help the body absorb nutrients and fluids, as well as to reduce the risk of infection. The SBS drug market is a subset of the larger gastrointestinal drug market, which includes drugs used to treat a variety of gastrointestinal disorders. The SBS drug market is relatively small, but is expected to grow in the coming years due to increasing awareness of the disorder and the development of new treatments. Some of the major companies in the SBS drug market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Takeda. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.